Title

Optimizing urinary tract infection outcomes: Nitrofurantoin versus fluoroquinolones

Authors

Shruti Vihang Brahmbhatt, Samarth Savaliya*, Mahavirsingh Rajput, Archana Patel

Affiliation

Department of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara- 391760, Gujarat, India; *Corresponding author

Email

Shruti Vihang Brahmbhatt - E-mail: dr.shruti1988@gmail.com

Samarth Savaliya - E-mail: samarthsavaliya98@gmail.com; Phone: +91 7567277557

Mahavirsingh Rajput - E-mail: drvirranawat@gmail.com

Archana Patel – E-mail: archanadrpj@gmail.com

Article Type

Research Article

Date

Received June 1, 2026; Revised June 30, 2026; Accepted June 30, 2026, Published June 30, 2026

Abstract

The rising global prevalence of urinary tract infections and escalating antimicrobial resistance present a critical clinical challenge. Therefore, it is of interest to evaluate the clinical cure rates while minimizing adverse drug reactions (ADRs) and resistance, researchers studied 40 adult patients (80% female) divided into Group I (Nitrofurantoin) and Group II (Fluoroquinolones). Nitrofurantoin achieved a higher clinical cure rate (95%) with 4.75 times greater odds of success than fluoroquinolones (80%). The adverse reaction rate was significantly lower for nitrofurantoin (10% versus 26.7%), though both groups reported similar side effects. Thus, data shows the nitrofurantoin also maintained a lower failure rate (5% versus 15%), supporting its prioritization as a first-line empirical therapy.

Keywords

Urinary tract infection (UTI), nitrofurantoin, fluroquinolones, adverse drug reaction (ADR), antibiotic stewardship

Citation

Brahmbhatt et al. Bioinformation 22(6): 3777-3781 (2026)

Edited by

P Kangueane  

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.